Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

5.640
+0.3105.82%
Volume:61.09M
Turnover:336.60M
Market Cap:35.44B
PE:7.77
High:5.640
Open:5.240
Low:5.230
Close:5.330
52wk High:5.668
52wk Low:4.340
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.54
T/O Rate:0.97%
Dividend:0.14
Dividend Rate:2.49%
EPS(LYR):0.726
ROE:8.96%
ROA:2.91%
PB:0.61
PE(LYR):7.77
PS:0.12

Loading ...

CR Sanjiu 2025 net profit attributable to shareholders rises 1.58% to RMB3.42 billion

Reuters
·
Mar 20

CR Boya Bio-pharmaceutical 2025 Profit Drops 71.61%; Revenue Rises 18.69%—Subsidiary of CHINARES PHARMA

Bulletin Express
·
Mar 20

China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025

Stock News
·
Mar 20

China Resources Pharmaceutical - FY Revenue RMB2.06 Bln for Cr Boya Bio-Pharmaceutical

THOMSON REUTERS
·
Mar 20

CR Boya Bio-pharmaceutical revenue rises 18.69% to RMB2.06 billion in 2025

Reuters
·
Mar 20

Jiang Zhong Pharmaceutical's Profit Jumps 15% in 2025

MT Newswires Live
·
Mar 20

China Resources Pharma (03320.HK) Subsidiary Dong-E-E-Jiao Posts 2025 Net Profit of RMB 1.74 Billion, Up 11.66%

Bulletin Express
·
Mar 19

China Resources Pharmaceutical Group Ltd - FY Revenue for Dong-E-E-Jiao RMB6.70 Bln

THOMSON REUTERS
·
Mar 19

CR Pharma (03320) Subsidiary KPC Records 46% Profit Decline in FY 2025, Revenue Falls 22%, Announces RMB 0.18 Cash Dividend Per Share

Bulletin Express
·
Mar 19

BRIEF-China Resources Pharmaceutical Says KPC Pharmaceuticals Proposes Dividend Of Rmb1.80 per 10 Shares

Reuters
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals FY Revenue RMB6.58 Bln

THOMSON REUTERS
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals Proposed to Distribute Cash Dividend of RMB1.80 for Every 10 Shares

THOMSON REUTERS
·
Mar 19

CR Double-Crane net assets attributable to shareholders rise 11.78% to RMB11.63 billion in 2025

Reuters
·
Mar 19

China Resources Pharmaceutical (03320) Discloses FY2025 Results of Subsidiary Tasly Pharmaceutical: Revenue Down 3.08%, Core Net Profit Up 15.63%

Bulletin Express
·
Mar 19

CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Stock News
·
Mar 19

CR Sanjiu affiliate Tasly Pharmaceutical reports 2025 net profit of RMB1.1 billion, up 15.63%

Reuters
·
Mar 19

CHINARES PHARMA (03320): Subsidiary CR Jiangzhong Delivers 15.03% Profit Growth in FY 2025, Proposes RMB0.88 Dividend per Share

Bulletin Express
·
Mar 19

China Resources Pharmaceutical - FY Revenue of Cr Jiangzhong Pharmaceutical RMB4.22 Bln

THOMSON REUTERS
·
Mar 19

CR Jiangzhong net profit attributable to shareholders rises 15.03% to RMB 0.91 billion

Reuters
·
Mar 19

China Resources Pharma Divests Tianmai Biotech Stake After Years of Unsuccessful Oral Insulin Bets

Deep News
·
Mar 17